Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.
Zhou, Diansong
Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach. [electronic resource] - CPT: pharmacometrics & systems pharmacology 07 2019 - 489-499 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
2163-8306
10.1002/psp4.12408 doi
Benzamides--pharmacokinetics
Clinical Trials, Phase I as Topic
Computer Simulation
Cytochrome P-450 CYP3A Inhibitors--pharmacokinetics
Drug Interactions
Humans
Models, Biological
Pyrazines--pharmacokinetics
Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach. [electronic resource] - CPT: pharmacometrics & systems pharmacology 07 2019 - 489-499 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
2163-8306
10.1002/psp4.12408 doi
Benzamides--pharmacokinetics
Clinical Trials, Phase I as Topic
Computer Simulation
Cytochrome P-450 CYP3A Inhibitors--pharmacokinetics
Drug Interactions
Humans
Models, Biological
Pyrazines--pharmacokinetics